STML - Stemline Therapeutics sees Elzonris Q4 revenues of $11.8M January, 13 2020 05:47 PM Stemline Therapeutics Inc. Stemline Therapeutics (NASDAQ:STML) -20.4% after-hours after announcing preliminary net revenues for Q4 and the full year.More news on: Stemline Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...